NASDAQ$WHWK
Whitehawk Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Aadi Bioscience's Q4 2023 earnings were announced, highlighting growth in FYARRO sales and progress in clinical trials.
Aadi Bioscience reported Q4 2023 revenue of $6.3 million from FYARRO sales, a 21% increase year-over-year. The company's net loss for the quarter was $16.3 million. They are on track with their PRECISION1 trial and initiated enrollment in two Phase 2 trials.
- FYARRO net product sales reached $6.3 million in Q4 2023, representing a 21% year-over-year growth.
- The PRECISION1 trial is on track to complete enrollment by May 2024, with an interim analysis expected in Q3 2024.
- Enrollment has begun for two Phase 2 trials investigating nab-sirolimus for neuroendocrine tumors (NETs) and advanced or recurrent endometrioid-type endometrial cancer (EEC).
- Cash, cash equivalents, and short-term investments totaled $108.8 million as of December 31, 2023, expected to fund operations into Q4 2025.
Headline financials
Revenue & EPS history
Aadi Bioscience · Revenue · Quarterly
$6.33M
Revenue by segment
Aadi Bioscience · $5.96M total across 1 segment · Q3 2023
- Product Sales, Net$5.96M—100.0%
Forward guidance
Aadi Bioscience anticipates continued advancements and growth, with expectations surrounding the timing of clinical trials and potential additional indications for FYARRO.
Tailwinds
- Cash runway extending into the fourth quarter of 2025.
- PRECISION 1 trial on track to complete enrollment by May 2024.
- PRECISION 1 two-thirds interim analysis expected in Q3 2024.
- Potential for additional indications for FYARRO.
- Continued advancements and growth expected.
Headwinds
- Uncertainties associated with clinical development and regulatory approval of FYARRO in additional indications.
- Potential delays in clinical trials for additional indications.
- Risk of unforeseen adverse reactions or side effects during commercialization and development.
- Reliance on third-party suppliers, some of which are sole suppliers.
- Risks related to estimates regarding future expenses, capital requirements, and the need for additional financing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+1.8%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+4.1%
Avg return
30 days after
37%
11 / 30 earnings
Positive
+69.8%
Q1 2021
Best reaction
-18.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -5.5% | -0.7% | |
| Q3 2025 | -0.4% | -3.5% | +10.2% | |
| Q1 2025 | +4.9% | -4.0% | -9.5% | |
| Q4 2024 | -1.5% | +1.2% | +14.7% | |
| Q3 2024 | +5.5% | +5.5% | +21.6% | |
| Q2 2024 | -3.6% | -1.4% | +30.7% | |
| Q1 2024 | -10.9% | -11.4% | -17.5% | |
| Q4 2023 | +5.7% | +9.3% | +1.0% | |
| Q3 2023 | -6.6% | -5.4% | +2.9% | |
| Q2 2023 | -1.0% | +1.7% | -12.2% | |
| Q1 2023 | -18.7% | -17.2% | -4.7% | |
| Q4 2022 | -1.8% | -0.1% | +10.3% | |
| Q3 2022 | +5.1% | +1.2% | +1.7% | |
| Q2 2022 | -6.2% | -0.9% | -11.0% | |
| Q1 2022 | +21.2% | +30.1% | +21.5% | |
| Q4 2021 | +5.4% | +2.3% | -8.2% | |
| Q3 2021 | -16.6% | -8.9% | -13.4% | |
| Q2 2021 | +3.0% | +2.0% | -7.9% | |
| Q1 2021 | +69.8% | +74.1% | +69.0% | |
| Q4 2020 | +1.9% | +2.5% | -15.1% | |
| Q3 2020 | -2.2% | +21.7% | +60.9% | |
| Q2 2020 | +17.3% | +6.4% | -22.4% | |
| Q1 2020 | -0.2% | -1.3% | +82.3% | |
| Q4 2019 | -5.8% | -17.7% | -6.2% | |
| Q3 2019 | -2.6% | -3.6% | +0.9% | |
| Q2 2019 | -1.9% | -1.9% | +0.9% | |
| Q1 2019 | -0.9% | -1.9% | -5.7% | |
| Q4 2018 | +4.2% | +22.4% | -65.0% | |
| Q3 2018 | -1.4% | -11.7% | -2.3% | |
| Q2 2018 | -1.7% | +3.9% | -3.8% | |
| Q4 2011 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro